LT2640358T - Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same - Google Patents
Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for sameInfo
- Publication number
- LT2640358T LT2640358T LTEP11808359.1T LT11808359T LT2640358T LT 2640358 T LT2640358 T LT 2640358T LT 11808359 T LT11808359 T LT 11808359T LT 2640358 T LT2640358 T LT 2640358T
- Authority
- LT
- Lithuania
- Prior art keywords
- dopa
- inhibitors
- catechol
- compositions
- same
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41363710P | 2010-11-15 | 2010-11-15 | |
| US201161524064P | 2011-08-16 | 2011-08-16 | |
| PCT/IL2011/000881 WO2012066538A1 (en) | 2010-11-15 | 2011-11-15 | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2640358T true LT2640358T (en) | 2018-03-26 |
Family
ID=45478410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP11808359.1T LT2640358T (en) | 2010-11-15 | 2011-11-15 | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US9421267B2 (en) |
| EP (3) | EP3326615B1 (en) |
| JP (3) | JP5902705B2 (en) |
| KR (1) | KR101859242B1 (en) |
| CN (2) | CN103442693A (en) |
| AU (1) | AU2011330757B2 (en) |
| BR (1) | BR112013011685B1 (en) |
| CA (1) | CA2817888C (en) |
| CL (1) | CL2013001368A1 (en) |
| CY (1) | CY1120005T1 (en) |
| DK (2) | DK2640358T3 (en) |
| ES (2) | ES2776734T3 (en) |
| HR (2) | HRP20180514T1 (en) |
| HU (2) | HUE047841T2 (en) |
| IL (1) | IL263954A (en) |
| LT (1) | LT2640358T (en) |
| MX (1) | MX348225B (en) |
| NZ (1) | NZ610911A (en) |
| PL (2) | PL2640358T3 (en) |
| PT (2) | PT3326615T (en) |
| RS (1) | RS57047B1 (en) |
| RU (2) | RU2740080C2 (en) |
| SG (2) | SG190258A1 (en) |
| SI (1) | SI2640358T1 (en) |
| SM (1) | SMT201800145T1 (en) |
| WO (1) | WO2012066538A1 (en) |
| ZA (1) | ZA201303509B (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3192500T3 (en) | 2009-05-19 | 2020-12-21 | Neuroderm Ltd | COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA-DECARBOXYLASE INHIBITORS |
| EP3326615B1 (en) | 2010-11-15 | 2020-01-08 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| ES2673219T3 (en) | 2010-11-15 | 2018-06-20 | Neuroderm Ltd | Composition for transdermal delivery of active agents |
| CN107693486A (en) | 2012-06-05 | 2018-02-16 | 纽罗德姆有限公司 | Composition comprising apomorphine and organic acid and application thereof |
| AU2014229127B2 (en) * | 2013-03-13 | 2018-04-05 | Neuroderm Ltd | Method for treatment of parkinson's disease |
| WO2015115512A1 (en) * | 2014-01-29 | 2015-08-06 | 独立行政法人産業技術総合研究所 | Method for preparing water extract of ashwagandha leaves which has enhanced anti-cancer activity utilizing cyclodextrin, and pharmaceutical composition containing ashwagandha leaves |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| HRP20201948T1 (en) | 2014-03-13 | 2021-01-22 | Neuroderm Ltd | DOPA-DECARBOCYLASE INHIBITOR PREPARATIONS |
| EP3188725B1 (en) | 2014-09-04 | 2020-10-28 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| KR20240113982A (en) | 2014-10-21 | 2024-07-23 | 애브비 인코포레이티드 | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease |
| MA41377A (en) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | LEVODOPA AND CARBIDONA INTESTINAL GEL AND PROCEDURES FOR USE |
| DK3277660T3 (en) | 2015-03-30 | 2020-01-27 | Berlirem Gmbh | Water-soluble L-DOPA esters |
| DK3075723T3 (en) | 2015-03-30 | 2017-09-11 | Berlirem Gmbh | High-resolution L-DOPA glycerol esters |
| WO2016179540A1 (en) | 2015-05-06 | 2016-11-10 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| WO2017039525A1 (en) * | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| JP2019515908A (en) * | 2016-04-20 | 2019-06-13 | アッヴィ・インコーポレイテッド | Carbidopa and L-dopa prodrugs and methods of use |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| CN106619490A (en) * | 2017-01-19 | 2017-05-10 | 云南白药集团无锡药业有限公司 | Levodopa transdermal patch and preparation method thereof |
| PT3634384T (en) | 2017-06-05 | 2021-04-29 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
| BR122020018051B1 (en) | 2017-07-07 | 2022-10-04 | Neuroderm Ltd | DEVICE FOR SUBCUTANEOUS APPLICATION OF FLUID DRUG |
| NZ768098A (en) | 2018-03-23 | 2025-12-19 | Lobsor Pharmaceuticals Ab | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
| TW202031265A (en) | 2018-11-15 | 2020-09-01 | 美商艾伯維有限公司 | Pharmaceutical formulations for subcutaneous administration |
| CN111701024B (en) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | Levodopa preparation and preparation method and application thereof |
| CN111643493B (en) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | High-concentration levodopa preparation and preparation method and application thereof |
| JP2023538859A (en) * | 2020-08-31 | 2023-09-12 | パーデュー、ファーマ、リミテッド、パートナーシップ | Compositions and methods for levodopa delivery |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| JP2025502857A (en) * | 2022-01-03 | 2025-01-28 | ニューロデルム，リミテッド | Methods and compositions for treating Parkinson's disease |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808317A (en) * | 1969-10-29 | 1974-04-30 | Alcon Labor Inc | Stabilized aqueous borate complexes of biologically active catechol amines |
| US3936495A (en) | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (en) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | Method for manufacturing high concentration preparations of DOPAs |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| DE252290T1 (en) | 1986-06-10 | 1988-06-09 | Chiesi Farmaceutici S.P.A., Parma | LEVODOPA METHYL ESTER CONTAINING PHARMACEUTICAL COMPOSITIONS, THEIR PRODUCTION AND THERAPEUTIC USE. |
| US4684666A (en) | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| WO1992007561A1 (en) | 1990-10-30 | 1992-05-14 | Ss Pharmaceutical Co., Ltd. | Antiphlogistic and analgesic gel preparation |
| US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US6245917B1 (en) | 1998-03-20 | 2001-06-12 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| EP1077692B1 (en) | 1998-05-15 | 2004-07-28 | Warner-Lambert Company LLC | Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same |
| US6274168B1 (en) | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| AU3490300A (en) | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (en) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Pharmaceutical composition |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (en) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method of producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| CN1496254A (en) * | 2000-12-15 | 2004-05-12 | ������ҩ������˾ | Treatment of male sexual dysfunction |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| US20050233945A1 (en) | 2003-07-18 | 2005-10-20 | Larry Brown | Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation |
| US6916813B2 (en) | 2001-12-10 | 2005-07-12 | Bristol-Myers Squibb Co. | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
| AU2003214551A1 (en) | 2002-04-11 | 2003-10-20 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical compositions of carbidopa and levodopa |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| BR0315221A (en) * | 2002-10-10 | 2005-08-23 | Morphochem Ag Komb Chemie | Compounds with antibacterial activity |
| DE10247233A1 (en) * | 2002-10-10 | 2004-06-17 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | New 4-substituted quinoline derivatives, useful for treating bacterial infections, optionally including additional ring nitrogens |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| US20050053669A1 (en) * | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| CA2543181A1 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (en) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| DK1797109T3 (en) | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| WO2006037061A2 (en) | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| CA2582346A1 (en) * | 2004-10-01 | 2006-04-13 | The Research Foundation Of State University Of New York | Morphine and morphine precursors |
| DE102006021872B4 (en) * | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, process for their preparation and their use as medicaments |
| RU2484815C2 (en) | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Continuous 24-hour introduction of levodopa/carbidopa into intestine |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| CA2682888A1 (en) | 2007-04-06 | 2008-10-16 | Transform Pharmaceuticals, Inc. | Systems and methods for delivering a fluid drug |
| CN101669925B (en) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | Dry powder inhalation, preparation method and application thereof |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| DK3192500T3 (en) * | 2009-05-19 | 2020-12-21 | Neuroderm Ltd | COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA-DECARBOXYLASE INHIBITORS |
| CN101987081B (en) | 2010-07-16 | 2012-08-08 | 钟术光 | Controlled release preparation |
| KR101187064B1 (en) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | Cationic lipid, method for manufacturing the same and delivery system comprising the same |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| EP3326615B1 (en) | 2010-11-15 | 2020-01-08 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| ES2673219T3 (en) | 2010-11-15 | 2018-06-20 | Neuroderm Ltd | Composition for transdermal delivery of active agents |
| US20140088192A1 (en) | 2010-12-10 | 2014-03-27 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| US20130116215A1 (en) | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
| AU2014229127B2 (en) | 2013-03-13 | 2018-04-05 | Neuroderm Ltd | Method for treatment of parkinson's disease |
| HRP20201948T1 (en) | 2014-03-13 | 2021-01-22 | Neuroderm Ltd | DOPA-DECARBOCYLASE INHIBITOR PREPARATIONS |
-
2011
- 2011-11-15 EP EP17207731.5A patent/EP3326615B1/en active Active
- 2011-11-15 BR BR112013011685-4A patent/BR112013011685B1/en active IP Right Grant
- 2011-11-15 KR KR1020137015306A patent/KR101859242B1/en active Active
- 2011-11-15 LT LTEP11808359.1T patent/LT2640358T/en unknown
- 2011-11-15 PT PT172077315T patent/PT3326615T/en unknown
- 2011-11-15 CA CA2817888A patent/CA2817888C/en active Active
- 2011-11-15 HR HRP20180514TT patent/HRP20180514T1/en unknown
- 2011-11-15 SG SG2013036678A patent/SG190258A1/en unknown
- 2011-11-15 PL PL11808359T patent/PL2640358T3/en unknown
- 2011-11-15 WO PCT/IL2011/000881 patent/WO2012066538A1/en not_active Ceased
- 2011-11-15 US US13/885,518 patent/US9421267B2/en active Active
- 2011-11-15 DK DK11808359.1T patent/DK2640358T3/en active
- 2011-11-15 ES ES17207731T patent/ES2776734T3/en active Active
- 2011-11-15 HU HUE17207731A patent/HUE047841T2/en unknown
- 2011-11-15 CN CN2011800648945A patent/CN103442693A/en active Pending
- 2011-11-15 JP JP2013538326A patent/JP5902705B2/en active Active
- 2011-11-15 DK DK17207731.5T patent/DK3326615T3/en active
- 2011-11-15 NZ NZ610911A patent/NZ610911A/en not_active IP Right Cessation
- 2011-11-15 PL PL17207731T patent/PL3326615T3/en unknown
- 2011-11-15 EP EP20150020.4A patent/EP3692982A1/en not_active Withdrawn
- 2011-11-15 HU HUE11808359A patent/HUE037005T2/en unknown
- 2011-11-15 AU AU2011330757A patent/AU2011330757B2/en active Active
- 2011-11-15 SI SI201131440T patent/SI2640358T1/en unknown
- 2011-11-15 EP EP11808359.1A patent/EP2640358B1/en active Active
- 2011-11-15 ES ES11808359.1T patent/ES2660772T3/en active Active
- 2011-11-15 CN CN201910369050.XA patent/CN110123743A/en active Pending
- 2011-11-15 RS RS20180386A patent/RS57047B1/en unknown
- 2011-11-15 RU RU2016147575A patent/RU2740080C2/en active
- 2011-11-15 SM SM20180145T patent/SMT201800145T1/en unknown
- 2011-11-15 RU RU2013123457A patent/RU2607497C2/en active
- 2011-11-15 SG SG10201509316SA patent/SG10201509316SA/en unknown
- 2011-11-15 MX MX2013005493A patent/MX348225B/en active IP Right Grant
- 2011-11-15 PT PT118083591T patent/PT2640358T/en unknown
-
2013
- 2013-05-15 CL CL2013001368A patent/CL2013001368A1/en unknown
- 2013-05-30 ZA ZA2013/03509A patent/ZA201303509B/en unknown
-
2014
- 2014-04-02 US US14/243,625 patent/US9040577B2/en active Active
- 2014-04-02 US US14/243,638 patent/US9040578B2/en active Active
-
2016
- 2016-03-10 JP JP2016047187A patent/JP6231145B2/en active Active
- 2016-07-13 US US15/209,423 patent/US20170157077A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017201780A patent/JP6387171B2/en active Active
-
2018
- 2018-03-06 CY CY20181100276T patent/CY1120005T1/en unknown
- 2018-12-24 IL IL263954A patent/IL263954A/en unknown
-
2020
- 2020-01-22 US US16/749,435 patent/US20200397730A1/en not_active Abandoned
- 2020-03-04 HR HRP20200366TT patent/HRP20200366T1/en unknown
-
2022
- 2022-03-16 US US17/696,243 patent/US20230047523A1/en not_active Abandoned
-
2024
- 2024-04-12 US US18/633,746 patent/US20250114315A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263954A (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same | |
| ZA201109037B (en) | Compositions for continuous administration of dopa decarboxylase inhibitors | |
| ZA201206223B (en) | Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof | |
| ZA201401117B (en) | Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof | |
| IL253911A0 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| IL210843A0 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| IL220863A (en) | Oxazole kinase inhibitors, pharmaceutical compositions comprising them and uses thereof | |
| IL230705A0 (en) | Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof | |
| EP2534145A4 (en) | Therapeutic methods and compositions involving allosteric kinase inhibition | |
| IL223865B (en) | Calcium salts of dihydroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof | |
| PL2642993T3 (en) | Compositions of rotigotine or pharmaceutically acceptable salts of rotigotine | |
| TN2013000239A1 (en) | New form of administration of enkephalinase inhibitor | |
| EP2424533A4 (en) | Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as -secretase inhibitors | |
| IL226239B (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same | |
| ZA201300009B (en) | Oral formulation of kinase inhibitors | |
| HK1177101A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |